Company Encyclopedia
View More
name
CRO Concept
CP00021.US
News
View More

Labcorp Unveils Plasma Detect MRD Technology Advancing Cancer Detection and Treatment

Labcorp Holdings Inc. has introduced Labcorp Plasma Detect™, a blood-based assay for detecting molecular residual disease (MRD) from circulating tumor DNA (ctDNA). Featured in Nature Medicine and Clinical Cancer Research, the assay has shown potential in tracking disease progression and improving post-surgical monitoring in cancer care. It may inform treatment strategies, particularly in diffuse pleural mesothelioma and head and neck cancer cases. The original content was published by Labcorp via PR Newswire on November 19, 2025.

Reuters·
US
LH
-0.60%
Reuters·
US
LH
-0.60%

MEDIA-Lone Star, Altaris, One Rock said among bidders for Lonza assets- Bloomberg News

– Source link: here – Note: Reuters has not verified this story and does not vouch for its accuracy

Reuters·
SG
O6Z
0.00%
US
LZAGY
-1.16%
Reuters·
SG
O6Z
0.00%
US
LZAGY
-1.16%

Could a Nobel Laureate’s Board Role at IQVIA (IQV) Reshape Its Scientific Leadership Narrative?

IQVIA Holdings appointed Nobel laureate Dr. William G. Kaelin Jr. to its board, effective November 5, 2025. His expertise in cancer research and governance may enhance IQVIA's scientific leadership and strategic direction. Despite this, immediate risks in the CRO market remain unchanged. IQVIA's Q3 2025 earnings exceeded expectations, showing resilience amid competitive pressures. The company forecasts $18.4 billion in revenue and $1.8 billion in earnings by 2028, with a fair value estimate of $246.84, offering a 14% upside.

Simplywall·
US
IQV
+0.54%
Simplywall·
US
IQV
+0.54%

Charles River Laboratories (CRL): Assessing Valuation After Latest Share Price Pullback

Charles River Laboratories International (CRL) shares have declined by 3% this week, raising investor concerns. Despite a 2.7% gain over the last three months, the stock shows a -13.2% return over the past year. Analysts suggest the stock is 13.9% undervalued with a fair value of $188.93, driven by expected recovery in biopharma demand and operational improvements. However, challenges like reliance on animal testing and demand softness in core services could impact future performance. Investors are encouraged to explore undervalued stocks and emerging opportunities in healthcare and biotech sectors.

Simplywall·
US
CRL
-0.13%
Simplywall·
US
CRL
-0.13%

Are Wall Street Analysts Bullish on IQVIA Holdings Stock?

Are Wall Street Analysts Bullish on IQVIA Holdings Stock?

Barchart Option·
US
IQV
+0.54%
Barchart Option·
US
IQV
+0.54%
Posts
View More